<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4661">
  <stage>Registered</stage>
  <submitdate>29/10/2013</submitdate>
  <approvaldate>29/10/2013</approvaldate>
  <nctid>NCT01976364</nctid>
  <trial_identification>
    <studytitle>Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis</studytitle>
    <scientifictitle>A Long-term, Open-label Extension Study Of Tofacitinib (Cp-690,550) For The Treatment Of Psoriatic Arthritis</scientifictitle>
    <utrn />
    <trialacronym>OPAL BALANCE</trialacronym>
    <secondaryid>2011-002169-39</secondaryid>
    <secondaryid>A3921092</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Arthritis, Psoriatic</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Tofacitinib
Treatment: drugs - Tofacitinib
Treatment: drugs - Methotrexate
Treatment: drugs - Placebo Methotrexate

Experimental: Tofacitinib - 


Treatment: drugs: Tofacitinib
Tofacitinib 5 mg tablet twice daily

Treatment: drugs: Tofacitinib
Tofactinib 10 mg tablet twice daily

Treatment: drugs: Methotrexate
Methotrexate 7.5-20 mg weekly

Treatment: drugs: Placebo Methotrexate
Placebo to match active methotrexate orally once a week

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) - Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to [study drug] was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.</outcome>
      <timepoint>Baseline up to Month 36</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of Participants With Laboratory Test Values of Potential Clinical Importance - Pre-defined criteria were established for each laboratory test to define the values that would be identified as of potential clinical importance.</outcome>
      <timepoint>Baseline up to Month 36</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With an American College of Rheumatology 20% (ACR20) Response - ACR20 response: greater than or equal to (=) 20 percent (%) improvement in tender joint count; = 20% improvement in swollen joint count; and = 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</outcome>
      <timepoint>Month 1, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21. Month 24, Month 27, Month 30, Month 33, Month 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response - ACR50 response: greater than or equal to (=) 50 percent (%) improvement in tender or swollen joint counts and 50% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.</outcome>
      <timepoint>Month 1, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24, Month 27, Month 30, Month 33, Month 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response - ACR70 response: greater than or equal to (=) 70 percent (%) improvement in tender or swollen joint counts and 70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.</outcome>
      <timepoint>Month 1, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21. Month 24, Month 27, Month 30, Month 33, Month 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Score on Health Assessment Questionnaire- Disability Index - Score on Health Assessment Questionnaire-Disability Index patient reported outcome</outcome>
      <timepoint>Month 1, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24, Month 27, Month 30, Month 33. Month 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of participants achieving Psoriatic Arthritis Response Criteria (PsARC) - PsARC is comprised of 4 clinical improvement criteria: 1 unit improvement on Physician Global Assessment: 20% (0-100 scale) improvement on the participant assessments; and 30% reduction in number of tender joints; and 30% reduction in the number of swollen joints. To achieve a clinical response, the participant must improve in 2 of the 4 PsARC criteria, 1 of which has to be the number of tender or swollen joints and none of the 4 scores could worsen</outcome>
      <timepoint>Month 1, Month 3, Month 6. Month 9, Month 12, Month 15, Month 18, Month 21, Month 24, Month 27, Month 30, Month 33, Month 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Physician's Global Assessment of Psoriasis score - PGA Psoriasis scale ranges from 0 (no psoriasis) to 5 (severe disease).</outcome>
      <timepoint>Month 1, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21. Month 24, Month 27, Month 30, Month 33, Month 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Psoriasis Area and Severity Index 75 (PASI) - Proportion of subjects achieving at least a 75% reduction in PASI relative to baseline and PASI component scores</outcome>
      <timepoint>Month 1, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24, Month 27, Month 30, Month 33, Month 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Dactylitis severity score - Dactylitis score is based upon digit tenderness for each digit of hands and feet ranges from 0-60.</outcome>
      <timepoint>Month 1, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24, Month 27, Month 30, Month 33, Month 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Enthesitis score based upon SPARCC (Spondylitis Research Consortium) and Leeds indices - Enthesitis score is based upon presence/absence of enthesitis at 16 sites (SPARCC) or 6 sites (Leeds)</outcome>
      <timepoint>Month 1, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24, Month 27, Month 30, Month 33, Month 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) - BASDAI is a validated self-assessment tool used to determine disease activity in participant with Ankylosing Spondylitis (AS) utilizing a visual analogue scale of 0-10 (0=none and 10=very severe). Answers to six questions measuring are averaged for a final score ranging from 0-10.</outcome>
      <timepoint>Month 1, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24, Month 27, Month 30, Month 33, Month 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>36-Item Short-Form Health Survey (SF-36) - SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).</outcome>
      <timepoint>Month 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Euro Quality of Life (EQ-5D)- Health State Profile Utility Score (EQ-5D) - EQ5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains; 1 indicates better health state (no problems) and 3 indicates worst health state.</outcome>
      <timepoint>Month 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Functional Assessment of Chronic Illness Therapy- Fatigue (FACIT-F) - FACIT-F is a participant rated questionnaire to assess fatigue</outcome>
      <timepoint>Month 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Previous participation in qualifying PsA study involving tofacitinib</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Time from End of Study visit of qualifying study is &gt;3 months.

          -  Pregnant female, breastfeeding female or female of childbearing potential unwilling or
             unable to use highly effective birth control for duration of study and one ovulatory
             cycle thereafter.

        Sub-study Inclusion Criteria:

          -  Subjects who have completed at least 24 months of treatment with tofacitinib in the
             extension study

          -  Subjects on a stable oral dose of methotrexate (maximum dose 20 mg per week)

        Sub-study 

        -Subjects who are receiving methotrexate by a route other than oral</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>17/02/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>686</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>2/01/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Rheumatology Research Unit - Maroochydore</hospital>
    <hospital>Pacific Private Clinic - Southport</hospital>
    <hospital>St. Vincent's Hospital (Melbourne) - Fitzroy</hospital>
    <hospital>Emeritus Research Pty Ltd - Victoria</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>4558 - Maroochydore</postcode>
    <postcode>4215 - Southport</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3145 - Victoria</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brabant Flamand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Genk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>MG</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>PR</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Pleven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Plovdiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Stara Zagora</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Ostrava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 4</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Uherske Hradiste</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mecklenburg-vorp</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt am Main</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Homburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Koeln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Olsberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Veszprem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>D.F</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Distrito Federal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Sinaloa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Yucatan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Chihuahua</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Dolnoslaskie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Mazowieckie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bydgoszcz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Elblag</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Grodzisk Mazowiecki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Nadarzyn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Torun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Karelia Republic</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Republic of Tatarstan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Novosibirsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saratov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Tomsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Yaroslavl</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bratislava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Martin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Rimavska Sobota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>A Coruna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cantabria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Chia-Yi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Essex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>West Midlands</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>West Yorkshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Wirral</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bath</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>York</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 3, long-term open-label extension study to evaluate the safety, tolerability
      and efficacy of tofacitinib in subjects with active PsA who have previously participated in
      randomized studies of tofacitinib for this indication.

      This study will include a sub-study to evaluate the efficacy, safety and tolerability of
      tofacitinib 5 mg BID administered as monotherapy after methotrexate withdrawal compared to
      tofacitinib 5 mg BID continued in combination with methotrexate. The sub-study will be
      available to subjects who have completed at least 24 months of participation in the
      open-label extension study and meet eligibility criteria for the sub-study.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01976364</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>